• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Surges 2%; US Inflation Rate Slows In October

    11/14/23 9:50:46 AM ET
    $AUVI
    $BCDA
    $INVO
    $KBNT
    Building Products
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AUVI alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones gaining around 400 points on Tuesday.

    Following the market opening Tuesday, the Dow traded up 1.16% to 34,736.95 while the NASDAQ rose 2.03% to 14,047.59. The S&P 500 also rose, gaining, 1.61% to 4,482.49.

    Check This Out: Top 4 Risk Off Stocks You'll Regret Missing In Q4

     

    Leading and Lagging Sectors

     

    Real estate shares surged by 3.9% on Tuesday.

    In trading on Tuesday, energy shares rose by just 0.2%.

     

    Top Headline

     

    The annual inflation rate in the U.S. eased to 3.2% in October versus 3.7% in both September and August, and compared to market estimates of 3.3%.

     

    Equities Trading UP

     

    BioCardia, Inc. (NASDAQ:BCDA) shares shot up 243% to $1.37 after the company announced the FDA approval of its Phase 3 clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.

    Shares of INVO Bioscience, Inc. (NASDAQ:INVO) got a boost, shooting 42% to $2.2857 after the company posted a narrower loss for the third quarter.

    Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) shares were also up, gaining 45% to $3.1002 after the company announced process to explore strategic alternatives.

     

    Equities Trading DOWN

     

    The Beauty Health Company (NASDAQ:SKIN) shares dropped 58% to $1.65 after the company reported weaker-than-expected financial results for its third quarter and revised its net sales outlook. Also, the company suspended its long-term full-year 2025 forecast.

    Shares of Kubient, Inc. (NASDAQ:KBNT) were down 56% to $0.0958. Kubient announced voluntary delisting from Nasdaq Capital Market.

    Applied UV, Inc. (NASDAQ:AUVI) was down, falling 44% to $0.1510. Applied UV announced pricing of $6.4 million upsized underwritten public offering of 42,666,666 units at $0.15 per unit.

    Also Check This Out: Oracle, Qualcomm And 2 Other Stocks Insiders Are Selling

     

    Commodities

     

    In commodity news, oil traded up 1.2% to $79.17 while gold traded up 0.6% at $1,962.50.

    Silver traded up 2.3% to $22.875 on Tuesday while copper rose 1.1% to $3.7050.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 gained 1%, London’s FTSE 100 rose 0.2% while Spain’s IBEX 35 Index rose 1.1% The German DAX rose 1.4% French CAC 40 rose 1%, while Italy’s FTSE MIB Index climbed 1.1%.

    The ZEW Indicator of Economic Sentiment for the Eurozone surged to 13.8 in November versus 2.3 in the previous month. The GDP in the Eurozone contracted 0.1% on quarter during the three months to September, while number of employed persons increased by 0.3% to 168.7 million people during the same period.

    The ZEW Indicator of Economic Sentiment for Germany climbed by 10.9 points to a reading of +9.8 in November, while Spanish annual consumer price inflation was confirmed at 3.5% for October. The number of job vacancies in the UK fell to 957,000 in August to October. Average weekly earnings, including bonuses in the UK, rose 7.9% year-over-year to GBP 673 per week while unemployment rate came in at 4.2% in the third quarter.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Tuesday, with Japan’s Nikkei 225 rising 0.34%, Hong Kong’s Hang Seng Index falling 0.17% and China’s Shanghai Composite Index gaining 0.31%.

    Indian wholesale prices fell by 0.52% year-over-year in October versus market expectations of a 0.2% decline.

     

    Economics

     

    The annual inflation rate in the U.S. eased to 3.2% in October versus 3.7% in both September and August, and compared to market estimates of 3.3%.

    Now Read This: Monday.Com To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday

    Get the next $AUVI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUVI
    $BCDA
    $INVO
    $KBNT

    CompanyDatePrice TargetRatingAnalyst
    The Beauty Health Company
    $SKIN
    9/19/2025$3.50Buy
    Roth Capital
    The Beauty Health Company
    $SKIN
    11/15/2023$11.00 → $1.50Buy → Hold
    Jefferies
    The Beauty Health Company
    $SKIN
    11/14/2023$10.00 → $2.50Buy → Hold
    Canaccord Genuity
    The Beauty Health Company
    $SKIN
    11/14/2023Neutral → Underweight
    JP Morgan
    The Beauty Health Company
    $SKIN
    11/14/2023$12.00 → $2.00Overweight → Underweight
    Piper Sandler
    The Beauty Health Company
    $SKIN
    11/14/2023$9.00 → $2.50Outperform → Market Perform
    TD Cowen
    The Beauty Health Company
    $SKIN
    11/14/2023Buy → Hold
    The Benchmark Company
    The Beauty Health Company
    $SKIN
    11/14/2023Mkt Perform → Underperform
    Raymond James
    More analyst ratings

    $AUVI
    $BCDA
    $INVO
    $KBNT
    SEC Filings

    View All

    BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BioCardia, Inc. (0000925741) (Filer)

    2/10/26 9:15:23 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by The Beauty Health Company

    SCHEDULE 13G/A - Beauty Health Co (0001818093) (Subject)

    2/6/26 9:58:03 AM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BioCardia, Inc. (0000925741) (Filer)

    2/3/26 8:00:08 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUVI
    $BCDA
    $INVO
    $KBNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,444 worth of shares (1,100 units at $1.31), increasing direct ownership by 0.41% to 267,966 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    12/17/25 6:32:43 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUVI
    $BCDA
    $INVO
    $KBNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart

    SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its Pre-Submission to FDA under its Q-Submission program for the approval of its Helix Transendocardial Delivery Catheter ("Helix") for intramyocardial therapeutic and diagnostic agent delivery.    The data supporting safety and effectiveness for the Helix Pre-Submission is from fifteen well-controlled clinical trials of cell and gene therapy delivery to the heart using Helix, where patients were enrolled in three primary cardiac clinical indications. The Helix

    2/10/26 9:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)

    SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced echocardiography data for the CardiAMP Cell Therapy for the treatment of heart failure has been accepted for Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics (THT) Meeting, which takes place March 2-4 in Boston, Massachusetts. On behalf of the CardiAMP HF investigators, the presentation will be made by Dr. Amish Raval, M.D., Professor of Medicine at UW School of Medicine and Public Health and CardiAMP HF Trial National Co-Principal

    2/3/26 8:00:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

    SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on our CardiAMP Cell Therapy intended for treatment of Heart Failure with Reduced Ejection Fraction (HFrEF). The meeting was held in further preparation for formal clinical consultation on acceptability of the existing clinical data for submission of an application for approval. Based on the discussions in the most recent meeting, PMDA said it will allow BioCardia to

    12/16/25 8:00:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUVI
    $BCDA
    $INVO
    $KBNT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,444 worth of shares (1,100 units at $1.31), increasing direct ownership by 0.41% to 267,966 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    12/17/25 6:32:43 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUVI
    $BCDA
    $INVO
    $KBNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on The Beauty Health Company with a new price target

    Roth Capital initiated coverage of The Beauty Health Company with a rating of Buy and set a new price target of $3.50

    9/19/25 8:39:00 AM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    The Beauty Health Company downgraded by Jefferies with a new price target

    Jefferies downgraded The Beauty Health Company from Buy to Hold and set a new price target of $1.50 from $11.00 previously

    11/15/23 7:13:27 AM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    The Beauty Health Company downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded The Beauty Health Company from Buy to Hold and set a new price target of $2.50 from $10.00 previously

    11/14/23 7:45:38 AM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    $AUVI
    $BCDA
    $INVO
    $KBNT
    Leadership Updates

    Live Leadership Updates

    View All

    BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

    SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served as Vice President of Quality and Regulatory. Prior to that, he served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical (a blood glucose monitoring device company), and as Dir

    11/24/25 8:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors

    LONG BEACH, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ:SKIN), home to flagship brand Hydrafacial, today announced the appointment of global aesthetics leader, Philippe Schaison, PharmaD, to its Board of Directors, effective as of October 30, 2025. Dr. Schaison has spent over 20 years leading organizations across the global aesthetics, biotech, and consumer health industries. He currently serves as Chief Executive Officer and a director of Soltégo, Inc., a bio-cosmetic company. Previously, Dr. Schaison was Chief Executive Officer NA of Syneron Candela, President of Allergan Aesthetics, and held senior leadership roles at Clarins, Johnson & Johnson, and L'Oré

    11/3/25 4:05:00 PM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    The Beauty Health Company Names Pedro Malha President and Chief Executive Officer

    Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1 Marla Beck Steps Down, With BeautyHealth Prepared for Its Next Phase of Growth LONG BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial, today announced the appointment of Pedro Malha as President and Chief Executive Officer, effective October 1, 2025. He succeeds Marla Beck, who is stepping down as President and CEO effective September 30, 2025, and will remain in an advisory role. Brent Saunders, Chairman of the Board, stated, "Pedro is an accomplished leader with broad industry experience at lea

    9/30/25 4:30:00 PM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    $AUVI
    $BCDA
    $INVO
    $KBNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by The Beauty Health Company

    SC 13G/A - Beauty Health Co (0001818093) (Subject)

    11/14/24 4:16:27 PM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by The Beauty Health Company

    SC 13G/A - Beauty Health Co (0001818093) (Subject)

    11/14/24 11:27:23 AM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by The Beauty Health Company

    SC 13G/A - Beauty Health Co (0001818093) (Subject)

    11/14/24 11:03:00 AM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    $AUVI
    $BCDA
    $INVO
    $KBNT
    Financials

    Live finance-specific insights

    View All

    BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2025 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. "This quarter's $6 million financing is actively supporting approvability discussions of CardiAMP

    11/12/25 4:40:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BeautyHealth Reports Third Quarter 2025 Financial Results

    LONG BEACH, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN) ("BeautyHealth" or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the third quarter ended September 30, 2025 ("Q3 2025"). "Our third-quarter results reflect disciplined execution and the continued strengthening of BeautyHealth's foundation," said BeautyHealth President and CEO, Pedro Malha. "Revenue of $70.7 million and Adjusted EBITDA of $8.9 million exceeded the top end of our guidance range, supported by ongoing operational efficiency. While device sales remained under pressure, the recurring consumables business continued to demonstrate resilience an

    11/6/25 4:05:00 PM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

    SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2025 by conference call on Wednesday, November 12, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10204565/1005a9b26d8. Please note that registered participants will receive their dial-in number upon registration. F

    11/5/25 7:29:23 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care